Abstract: The present invention relates to compounds capable of forming metal-organic frameworks (MOFs), particularly f-block metal MOFs which selectively sorb one component (e.g. para-xylene) from a mixture of components (e.g. m-/p-xylene mixture). The invention also relates to methods of producing and using said compounds.

Abstract: Provided are siRNA molecules that are particularly efficient in their ability to reduce transcription and expression of TNF or IL-1? in canine macrophage and synovial cells. The siRNA molecules demonstrate improved silencing of TNF or IL-1? as compared to siRNA molecules disclosed prior to the present invention. These properties are demonstrated in accepted experimental models of osteoarthritis, and particularly canine osteoarthritis. The siRNA molecules of the invention, may be employed in pharmaceutical compositions for use in the prevention and/or reduction of osteoarthritis in dogs. The inventors have found that encapsulation of the siRNAs in small PLGA microspheres confers surprisingly advantageous properties.

Abstract: Graphitic carbon nitride has been prepared and its structure confirmed by extensive characterization. This material has useful electronic, in particular semiconducting, properties. Crystalline thin films have been prepared. Synthesis may be carried out by condensation of unsaturated carbon- and nitrogen-containing compound(s) in inert solvent such as a salt melt, forming graphitic carbon nitride at a gas-liquid or solid-liquid interface.

Abstract: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing a single phase solution comprising: (a) a solvent or a mixture of miscible solvents, (b) a liquid carrier material, which is soluble in solvent (a), and (c) a dopant material which is also soluble in solvent (a); (II) cooling (preferably freezing) the single phase solution produced in step (I) to a temperature at which at least both the solvent (a) and carrier material (b) become solid; and (III) removing solid solvent (a) from the cooled (frozen) single phase solution in vapor form, such that the remaining cooled (frozen) carrier material (b) and dopant material (c) are returned to ambient temperature thus providing a product of liquid carrier material (b) having dopant material (c) dispersed therein.

Abstract: Particles comprising a branched polymer and either a block copolymer or a linear dendritic hybrid represent a category of useful materials. They may be used in for example drug delivery applications. They may be prepared by a method comprising the steps of: dissolving the branched polymer and block copolymer or linear dendritic hybrid, and optionally other component(s), in a solvent to form a solution; adding said solution to a different liquid; and removing said solvent to form a dispersion of co-precipitated particles.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: Compounds are disclosed that inhibit the methylerythritol cytidyltransferase (IspD) enzyme in the non-mevalonate pathway (MEP pathway), which is present in many organisms including the P. falciparum parasite. Inhibitors of the IspD enzyme in the non-mevalonate pathway of the P. falciparum parasite are useful for treating malaria.

Abstract: A host material may be used for the separation of elements or compounds, wherein the host material is an organic molecular solid with suitable cavities for accommodating a guest material to be separated, and with interconnections between the cavities to allow the guest material to diffuse through the host material, and wherein said interconnections are closed for a proportion of the time or have a static pore limiting diameter which is smaller than the static dimension of the guest material. Applications include separations of rare gases, chiral molecules, and alkanes. One class of suitable host materials may be made by imine condensation.

Abstract: Provided are fusion proteins, polynucleotides and expression vectors with therapeutic utility in the prevention and/or treatment of cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.

Abstract: The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof.

Abstract: The invention concerns the use of a food additive including a sweetener in the feed or the drink of a ruminant animal to reduce the impact of stressful conditions on intestinal mucosa quality.

Abstract: The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof.

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

Abstract: The present invention disclosed a method of producing a three-dimensional porous tissue in-growth structure. The method includes the steps of depositing a first layer of metal powder and scanning the first layer of metal powder with a laser beam to form a portion of a plurality of predetermined unit cells. Depositing at least one additional layer of metal powder onto a previous layer and repeating the step of scanning a laser beam for at least one of the additional layers in order to continuing forming the predetermined unit cells. The method further includes continuing the depositing and scanning steps to form a medical implant.

Abstract: Provided is an osteoinductive material comprising a substrate; and a layer of a hydrocarbyl group comprising 10 to 12 carbon atoms, the hydrocarbyl group having one end attached to the substrate and a presenting amine (—NH2) group at the unattached end. The hydrocarbyl group may be 11 carbons long, and may be provided in the form of 11-aminoundecyltriethoxysilane. The substrate may be a glass; metal; polymer; ceramic; plastic; or hydroxyapatite. The substrate may, for example, be a metal selected from the group consisting of: titanium; titanium alloys; cobalt chrome; and steel. An osteoinductive material may be provided in the form of a medical implant, or part thereof, such as an orthopaedic implant or a dental implant or part thereof. Alternatively the substrate may be in the form of a cell culture vessel. Also provided is a method of producing such osteoinductive materials, the medical use of such materials, and a method of producing bone or a bone precursor utilising the disclosed materials.

Abstract: The invention relates generally to oligosaccharide compounds and the use of these compounds as pharmaceuticals for treating diseases or conditions in which it is desirable to inhibit ?-secretase.

Abstract: A method for preparing a conjugated microporous polymer comprises the coupling of an alkynyl aryl monomer having a plurality of terminal alkyne groups with an iodo- or bromo-aryl monomer having a plurality of halogen atoms in the presence of a palladium (0) catalyst. The conjugated microporous polymer comprises nodes comprising at least one aryl unit and struts comprising at least one alkyne unit and at least one aryl unit, wherein a node is bonded from its aryl unit or units to at least two struts via alkyne units. Such polymers are useful in numerous areas such as separations, controlled release, gas storage and supports for catalysts.

Abstract: The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at GABAA.

Abstract: The present invention relates to a dental implant and to a process for fabricating the dental implant.

Abstract: The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.